HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver

This article was originally published in The Rose Sheet

Executive Summary

Nexxus and Tresemme fueled a 9.2% increase in global consumer products sales to $360 mil. during the third quarter (ended June 30), and earnings before income taxes for the unit advanced 9.2% to $32.6 mil., Alberto announces July 27. The beauty supply business, which includes Sally Beauty and Beauty Systems Group, had sales of $599.5 mil., representing growth of 4%, while earnings before income taxes for the division were up 8.6% to $65.5 mil. Alberto's net sales in Q3 increased 6% to $952.7 mil. Due to a $50 mil. termination fee associated with the failed merger of Alberto's beauty supply business with Regis Corporation, Alberto's net earnings plummeted 42.9% to $30.5 mil., including non-core items. Alberto recently announced it will spin off Sally as a separate entity in a transaction expected to close in December (1"The Rose Sheet" June 26, 2006, p. 3)...

You may also be interested in...



Alberto-Culver Eyes Acquisitions Following Sally Spin-Off

Alberto-Culver's consumer products division will make acquisitions a top priority following the spin-off of Sally Beauty Company, the firm stated during a June 19 call announcing the decision

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel